Tag: Boston Scientific

One-year results show ‘superior’ primary patency rate for Eluvia DES compared...

One-year results presented at Vascular Interventional Advances (VIVA) 2021 in Las Vegas (Oct. 5–7) from the EMINENT trial demonstrated the superiority of the Eluvia...

Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy

Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results...

Boston Scientific and BD initiate venous stent recalls

Boston Scientific and BD have both initiated recalls of venous stents. According to a Food and Drug Administration (FDA) medical device recall notice posted...

Boston Scientific recalls Vici SDS and Vici RDS venous stent systems...

According to a medical device recall notice posted on the Food and Drug Administration (FDA) website, Boston Scientific has recalled its Vici venous stent...

Radiation exposure: ControlRad Select imaging system gains FDA market clearance

ControlRad has announced Food and Drug Administration (FDA) 510(k) clearance to market ControlRad Select, a technology that utilizes proprietary semi-transparent filters, a user-interface tablet,...